Page last updated: 2024-09-05

cilengitide and Pancreatic Neoplasms

cilengitide has been researched along with Pancreatic Neoplasms in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (20.00)	29.6817
2010's	4 (80.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Cabarcas, SM; Farrar, WL; Mathews, L; Sun, L; Thomas, S; Zhang, X	1
Bridges, E; Harris, AL	1
Alrawashdeh, W; Cereser, B; Crnogorac-Jurcevic, T; Demircioglu, F; Elia, G; Ghazaly, E; Hagemann, T; Hodivala-Dilke, KM; Kocher, HM; McDonald, S; Scudamore, CL; Stratford, MR; Wong, PP	1
Oron, Y	1
Balcke, P; Castellano, D; Davidson, N; Dittrich, C; Dobrowolski, F; Esteve, AA; Friess, H; Hawkins, R; Herzog, P; Hossfeld, DK; Katz, F; Kleeff, J; Kovar, A; Langrehr, JM; Neyns, B; Niedergethmann, M; Nippgen, J; Oettle, H; Piedbois, P; Raedle, J; Scheithauer, W; Stöger, H; Tempia-Caliera, AA; van Belle, S; Vermorken, J	1

Reviews

1 review(s) available for cilengitide and Pancreatic Neoplasms

Article	Year
Integrin-based therapy of pancreatic adenocarcinoma: current status and future perspectives. Minerva gastroenterologica e dietologica, 2015, Volume: 61, Issue:2 Topics: Adenocarcinoma; Clinical Trials as Topic; Forecasting; Humans; Integrins; Pancreatic Neoplasms; Snake Venoms	2015

Trials

1 trial(s) available for cilengitide and Pancreatic Neoplasms

Article	Year
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC cancer, 2006, Dec-11, Volume: 6 Topics: Adult; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Cell Division; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Quality of Life; Snake Venoms; Surveys and Questionnaires; Survival Rate	2006

Article

Year

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.

BMC cancer, 2006, Dec-11, Volume: 6

Topics: Adult; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Cell Division; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Quality of Life; Snake Venoms; Surveys and Questionnaires; Survival Rate

2006

Other Studies

3 other study(ies) available for cilengitide and Pancreatic Neoplasms

Article	Year
The differentiation of pancreatic tumor-initiating cells by vitronectin can be blocked by cilengitide. Pancreas, 2013, Volume: 42, Issue:5 Topics: Biomarkers, Tumor; Cell Differentiation; Cell Line, Tumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Integrin alphaVbeta3; Neoplastic Stem Cells; Pancreatic Neoplasms; Receptors, Vitronectin; Reverse Transcriptase Polymerase Chain Reaction; Serum; Snake Venoms; Spheroids, Cellular; Tumor Cells, Cultured; Vitronectin	2013
Vascular-promoting therapy reduced tumor growth and progression by improving chemotherapy efficacy. Cancer cell, 2015, Jan-12, Volume: 27, Issue:1 Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Lewis Lung; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Snake Venoms; Verapamil	2015
Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. Cancer cell, 2015, Jan-12, Volume: 27, Issue:1 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreas; Pancreatic Neoplasms; Snake Venoms; Verapamil	2015